Back to list

EMPA-KIDNEY

University of North Carolina at Chapel Hill


Description

Scientists are searching for new treatments to reduce the risk of kidney and heart problems in people with kidney disease. There is now a new medication called empagliflozin which was originally developed to treat high blood sugar in people with diabetes but has recently been shown to have beneficial effects on both the heart and kidney.


Keywords:

Diabetes, Kidneys


Category:

Drug or Biologic
Phase:3

Qualifications

 


Age
18 - 0 years


Gender
Any


Study Population

Adult with chronic kidney disease but not on the transplant list, not on dialysis and not transplanted.


Investigator

Amy Mottl
Clinical Associate Professor
Medicine-Nephrology

For questions, contact:

Anne Froment
anne_froment@med.unc.edu
(919) 445-2622


Recruitment Period End

April 30, 2019

Location

Primary Location
Clinical and Translational Research Center
Burnett-Womack Building, 160 Dental Cir, Chapel Hill, NC 27514, USA

Study Qualifications

Gender Any

Age Range 18 - 0 years

Participant qualification(s) having chronic kidney disease (your kidneys are not working as well as they should)

Not eligible if: on dialysis, having received a transplant, or on the transplant waiting list

Number of Visits

    » 10 In person visit(s)

    1 scrreening, one 2 months visit, one 6 months visit then one visit every 6 months

    » 0 Remote visit(s)

Participation Period

4 years

Compensation

$50 per completed visit

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.